|
|
Post by mannmade on Sept 17, 2014 12:15:48 GMT -5
|
|
|
|
Post by mnkdd on Sept 17, 2014 12:23:09 GMT -5
Al just said it was too complex and costly. He said Afrezza w/ Basal is just as good for most people.
|
|
|
|
Post by papihoyos on Sept 17, 2014 12:27:42 GMT -5
|
|
|
|
Post by mannmade on Sept 17, 2014 13:37:25 GMT -5
Al just said it was too complex and costly. He said Afrezza w/ Basal is just as good for most people. I tend to agree (with what I know) but it is the start... Technology gets smaller and less costlier faster every year... Also know by some as "Moore's Law" so it does provide food for thought... |
|
|
|
Post by seanismorris on Sept 17, 2014 13:54:38 GMT -5
My take is the bionic pancreas is it's more useful for Type 1.
When basal insulin lasts a week or two the BP becomes a lot less useful. Add that to Afrezza and compliance becomes a lot less of an issue.
I still like CGM's because it gets almost live data in doctors hands, that should result in better diabetes treatments (lowering the cost of diabetes).
I'm not sure a BP will have any effect on Afrezzas sales. A BP plus Afrezza would still be better than a BP alone.
|
|
|
|
Post by mannmade on Sept 17, 2014 15:00:33 GMT -5
My take is the bionic pancreas is it's more useful for Type 1. When basal insulin lasts a week or two the BP becomes a lot less useful. Add that to Afrezza and compliance becomes a lot less of an issue. I still like CGM's because it gets almost live data in doctors hands, that should result in better diabetes treatments (lowering the cost of diabetes). I'm not sure a BP will have any effect on Afrezzas sales. A BP plus Afrezza would still be better than a BP alone. I tend to agree with you, especially in the near term... However I like to invest for the long term so am always on the look out for relevant events and news that could effect my strategy... If the bionic pancreas debut's in 2017 as mentioned and does get some serious BP interest or other funding it could become an opportunity for T1's that would be significant in controlling their Blood Sugar etc... For T2's assuming the switch from GLP-1's and Basal takes place with Afrezza becoming the first use medication I think we would be fine for quite some time but if the Bionic Pancreas does everything automatically, e.g.; constant monitoring/measuring of Blood Sugar for fasting and spikes during food intake, it might be an opportunity for Afrezza as will need some form of insulin. Just not sure how would work as not inhaled... I do know, as many recall that Samsun is using Afrezza with the Artificial Pancreas trials in SB. So just "food" for thought and other info about what is going on that could drive the direction of treatment in the future... |
|
|
|
Post by seanismorris on Sept 17, 2014 17:30:10 GMT -5
I'd characterize the bionic pancreas as a souped up insulin pump. Here's an example of why they won't be a blockbuster device. www.medpagetoday.com/MeetingCoverage/EASD/47705Basically, costly and too complicated. Maybe someday, but that's a long way way. Exactly, the opposite of the reasons that Afrezza will succeed. |
|
|
|
Post by mnholdem on Sept 20, 2014 8:10:00 GMT -5
Al just said it was too complex and costly. He said Afrezza w/ Basal is just as good for most people. But look how Al simplified pacemakers years ago. I'm eager to see what Al's Medallion Pharmaceuticals inplantable infusion pump can do. Self-monitoring, upgradeable wireless software platform, simple to use... and inexpensive? If anyone can pull all that off, it's Alfred Mann, in spite of what he said about Toujeo/Afrezza being a better, cheaper choice. Besides the Medallion pump is designed for more than just diabetes treatment. |
|
